Control of venom-induced tissue injury in copperhead snakebite patients: a post hoc sub-group analysis of a clinical trial comparing F(ab')2 to Fab antivenom.
Clin Toxicol (Phila)
; 60(4): 521-523, 2022 Apr.
Article
in En
| MEDLINE
| ID: mdl-34590543
ABSTRACT
INTRODUCTION:
Fab antivenom (FabAV) halts progression of tissue injury and improves recovery in copperhead snakebite. It is unknown if F(ab')2AV does as well. The objective of this study was to compare control of tissue injury in copperhead snakebite patients treated with F(ab')2AV versus FabAV.METHODS:
We performed a post hoc analysis of copperhead envenomated patients in a clinical trial comparing F(ab')2AV to FabAV. The outcomes for this analysis are the number of repeat doses required to obtain initial control, the number of patients requiring unscheduled doses during maintenance, and the time from antivenom administration to initial control.RESULTS:
Twenty-one (13 F(ab')2AV, 8 FabAV) were copperhead patients. Median age was 46 years with a male predominance. Baseline severity was similar. One (8%) F(ab')2AV and 2(25%) FabAV patients required repeat initial dosing, difference = 17%, (95%CI -18, 57%). One (8%) F(ab')2AV and 1(13%) FabAV patients required additional doses after maintenance, difference = 5%, (95%CI -27, 45%). Median time to initial control was 2.7 range (2.0, 9.3) hours and 3.5 range (2.0, 7.4) for F(ab')2AV and FabAV respectively, difference -0.8 h (95% CI -2.6, 0.9).CONCLUSIONS:
This exploratory analysis suggests that the available measures of the control of venom-induced tissue injury are similar between antivenom subgroups.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Snake Bites
/
Agkistrodon
/
Crotalid Venoms
Type of study:
Clinical_trials
Limits:
Animals
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Clin Toxicol (Phila)
Journal subject:
TOXICOLOGIA
Year:
2022
Document type:
Article
Affiliation country:
United States